The quantum and strength of evidence are strongest for baricitinib among the different JAK-STAT inhibitors (Zhang X. et al., 2022) and for tocilizumab among the various IL-6 inhibitors (WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group et al., 2021). This evidence concerns the gene SOAT1 and COVID-19.